Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

1.4K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.4K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

2.7K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
2.7K
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

890
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
890
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

444
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
444
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

522
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
522
Angina IV: Management01:26

Angina IV: Management

493
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
493

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Machine Learning With Genetic and Clinical Data to Predict Ischemic Outcomes After PCI.

Clinical and translational science·2026
Same author

Toxicological insights into formaldehyde-induced copd: a study on gene expression and molecular interactions.

Cytotechnology·2026
Same author

Impact of CYP2C19 and CYP3A4 Inhibitor Use on Clopidogrel Clinical Effectiveness in CYP2C19 Genotyped Patients Undergoing Percutaneous Coronary Intervention.

Clinical pharmacology and therapeutics·2026
Same author

2025 Acute Coronary Syndrome Guideline: Missing the Boat on <i>CYP2C19</i> Genotyping.

Journal of the American Heart Association·2026
Same author

Post-PCI Physiological Testing: Phenotyping Future Failure.

JACC. Cardiovascular interventions·2026
Same author

Pharmacological evaluation of selected medicinal plant extracts against multidrug-resistant Klebsiella pneumoniae: implications for inflammation-associated respiratory infections.

Inflammopharmacology·2026

相关实验视频

Updated: May 2, 2026

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

11.1K

在用冠状动脉内β-阻断剂进行皮肤冠状动脉干预期间,保护远端心肌.

Fen Wei Wang1, Abdulfatah Osman, Javier Otero

  • 1Department of Internal Medicine, Division of Cardiology, The University of Texas Medical Branch at Galveston, 301 University Blvd, 5.106 JSHA, Galveston, Tex 77555-0553, USA.

Circulation
|May 29, 2003
PubMed
概括

冠状动脉内醇显著降低肌动脉梗塞和皮肤冠状动脉干预 (PCI) 后的不良结果. 这种β抑制剂治疗可以在PCI过程中保护心脏,改善患者的康复.

更多相关视频

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in G&#246;ttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

9.0K
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

7.7K

相关实验视频

Last Updated: May 2, 2026

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

11.1K
Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in G&#246;ttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

9.0K
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

7.7K

科学领域:

  • 心脏病学 心脏病学
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 静脉注射β-阻塞剂可以减少冠状动脉封闭期间心肌损伤.
  • 在皮肤冠状动脉干预 (PCI) 期间,冠状动脉内罗可延迟心肌缺血.

研究的目的:

  • 测试冠心内罗能否在PCI期间保护缺血性心肌免受损伤.
  • 为了确定ICpropranolol是否可以减少心肌梗塞 (MI) 和PCI后的短期不良结果.

主要方法:

  • 接受PCI的150名患者被随机分配给接受IC普罗普拉诺洛尔 (n=75) 或安慰剂 (n=75).
  • 在气球充气之前,研究药物被输入冠状动脉.
  • 生物化学标志物和临床结果被评估长达30天.

主要成果:

  • 心肌梗塞 (MI) 发生在17%的propranolol患者和36%的安慰剂患者中 (P=0.01).
  • 在13%的普拉拉诺洛尔患者和33%的安慰剂患者 (P=0.005) 观察到托罗邦升.
  • 死亡,心脏病发作或紧急再血管化的复合终点发生在18%的普拉诺洛尔患者和40%的安慰剂患者中 (P=0.004).

结论:

  • 冠心内罗 (propranolol) 的使用可以在PCI期间保护心肌.
  • 这种治疗显著降低了心脏病发病率,并改善了短期的临床结果.